ABCURO
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.
ABCURO
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Website Url:
http://www.abcuro.com
Total Employee:
1+
Status:
Active
Contact:
(617) 714-9759
Total Funding:
59.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx Sitelinks Search Box
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Board_member
2021-01-01
Board_member
2021-01-01
Board_member
2021-01-01
Board_member
2021-01-01
Board_member
2021-01-01
Board_member
2021-01-01
Current Employees Featured
David de Graaf President & CEO @ Abcuro
President & CEO
2020-09-01
Stefano Gullà CEO @ Abcuro
CEO
2016-12-01
Darlene Deptula-Hicks Board Member & Audit Committee Chair @ Abcuro
Board Member & Audit Committee Chair
2021-07-01
Founder
Investors List
Mass General Brigham Ventures
Mass General Brigham Ventures investment in Series A - Abcuro
Hongsen Investment Group
Hongsen Investment Group investment in Series A - Abcuro
RA Capital Management
RA Capital Management investment in Series A - Abcuro
Samsara BioCapital
Samsara BioCapital investment in Series A - Abcuro
Pontifax
Pontifax investment in Series A - Abcuro
Sanofi Ventures
Sanofi Ventures investment in Series A - Abcuro
Kaitai Capital
Kaitai Capital investment in Series A - Abcuro
ShangPharma Innovation
ShangPharma Innovation investment in Series A - Abcuro
Partners Innovation Fund
Partners Innovation Fund investment in Series A - Abcuro
Official Site Inspections
http://www.abcuro.com Semrush global rank: 4.75 M Semrush visits lastest month: 1.97 K
- Host name: 240.146.169.192.host.secureserver.net
- IP address: 192.169.146.240
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Abcuro"
About - Abcuro
Abcuro is developing ABC008 for autoimmune disorders. ABC008 is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting KLRG1 (killer cell lectin-like …See details»
Abcuro - Crunchbase Company Profile & Funding
Organization. Abcuro . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Abcuro develops immunotherapies to treat …See details»
Home - Abcuro
Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease. Newton, Massachusetts, March 11, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies …See details»
Board of Directors - Abcuro
Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the …See details»
Abcuro, Inc - LinkedIn
Abcuro, Inc | 3,135 followers on LinkedIn. Developing immunotherapies for autoimmune diseases and cancer | Abcuro is a clinical stage biotechnology company developing treatments for …See details»
Abcuro 2025 Company Profile: Valuation, Funding & Investors
Abcuro General Information Description. Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer. The company uses proprietary analysis of …See details»
Abcuro - Contacts, Employees, Board Members, Advisors
Organization. Abcuro . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. ... Abcuro has 6 board …See details»
Abcuro - Org Chart, Teams, Culture & Jobs - The Org
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune …See details»
Abcuro Company Profile - Office Locations, Competitors, Revenue …
Abcuro is a company developing immunotherapies to treat autoimmunity and cancer. It offers a monoclonal antibody ABC008 that depletes cytotoxic T cells by targeting killer cell lectin-like …See details»
Abcuro - Products, Competitors, Financials, Employees, …
Abcuro's products are designed to selectively deplete harmful cells or reactivate inhibited cells within the body's immune system. It was founded in 2015 and is based in Newton, …See details»
Abcuro - Bain Capital Life Sciences
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly …See details»
Abcuro | The Healthcare Technology Report.
Abcuro is empowering patients with IBM by advancing the clinical development of a novel therapeutic medicine that has the potential to preserve and maintain muscle strength. The …See details»
Abcuro - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Abcuro, Inc. Company Information - Funding, Investors, and More
Get information on funding, investors, industries, and more for Abcuro, Inc.. See Abcuro, Inc. company profile and funding data.See details»
Abcuro - Overview, News & Similar companies | ZoomInfo.com
Dec 6, 2023 Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., …See details»
Abcuro raises $200m to take muscle disease drug to market
Feb 12, 2025 Abcuro's Series B, completed in August 2023, raised $155 million. "IBM is a tremendously debilitating disease, which drastically and irreversibly reduces quality of life," …See details»
Pipeline - Abcuro
Abcuro is advancing first-in-class programs in autoimmunity and cancer in which highly cytotoxic immune cells play a critical role. ABC008. ABC008 is a first-in-class anti-KLRG1 antibody …See details»
Abcuro Announces $200 Million Financing to Advance its First-In …
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly …See details»
Abcuro, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Abcuro also plans to take early-stage clinical data in patients with T cell large granular lymphocytic leukemia to the FDA in the “coming quarter or two” to see about a Phase 2/3 …See details»
News - Abcuro
Nov 5, 2019 Newton, Massachusetts, March 11, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and …See details»